Track topics on Twitter Track topics that are important to you
Operating expenses in line with Company's acceleration of drug development activities and corporate growth Genkyotex's cash runway extends through Q1 2019 Two Phase II clinical trials ongoing for ...
Regulatory News: Genkyotex (Paris:GKTX) (Brussels:GKTX) (Euronext Paris Brussels: FR00011790542 GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that it will par...
Cash, cash equivalents and liquid investments of €14.6 million as of December 31st, 2017, in line with Company's expectations Phase 2 trial of GKT831 in Primary Biliary Cholangitis on track with i.....
Cash and cash equivalents of €12.5 million as of March 31st, 2018, in line with expectations Cash runway to Q3 2019 Company now expects interim results from phase 2 trial of GKT831 in Primary Bili.....
SummaryGenKyoTex SA GenKyoTex, formerly Genticel SA is a drug company that develops NOX therapies. The company develops targeted NOX inhibitors. It develops molecule therapeutics that inhibits the NOX...
Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyot...
We have published hundreds of Genkyotex news stories on BioPortfolio along with dozens of Genkyotex Clinical Trials and PubMed Articles about Genkyotex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genkyotex Companies in our database. You can also find out about relevant Genkyotex Drugs and Medications on this site too.
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...